Genesis Research Group Appoints Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR
August 11, 2026 | HEOR, Market Access, Pharma, RWE, biotech, genesis, pharmaceutical
Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence (RWE) and health economics and outcomes research (HEOR) business.
Sarah is an accomplished executive with extensive experience leading evidence generation, healthcare analytics, and research organizations across the life sciences industry. Most recently, she served as President of Avalere, where she led the delivery of evidence generation, health economics, policy, and market access solutions for life sciences, payer, and advocacy clients.
Prior to that, Sarah founded and scaled Ontada, McKesson’s oncology research business, where she built a scientific organization that produced more than 200 peer-reviewed publications, advanced innovative real-world evidence strategies, and supported multiple regulatory submissions. Earlier in her career, she held leadership roles at Humana, Givaudan, and Brown-Forman.
David W. Miller, Chief Executive Officer, said:
“Sarah is a highly respected leader with an exceptional track record of combining scientific excellence, operational leadership, and commercial insight. As our clients increasingly seek integrated evidence strategies to support decisions across development, access, and commercialization, Sarah’s experience and vision make her exceptionally well positioned to lead our RWE/HEOR business as we continue into our next phase of growth. We are delighted to welcome her to Genesis.”
Sarah holds bachelor’s, master’s, and doctoral degrees in Chemical Engineering. She has authored numerous scientific publications, holds multiple patents, is an active member of ISPOR, and is a frequent speaker on real-world evidence and healthcare innovation.
Sarah Alwardt, Executive Vice President, RWE/HEOR, commented:
“What attracted me to Genesis was the opportunity to join a team that combines scientific rigor with deep expertise in HEOR, real-world evidence, and market access. As healthcare becomes increasingly data-driven, clients need partners who can connect evidence, stakeholder insights, and strategy to support better decision-making. Genesis is uniquely positioned to bring together expertise across disciplines, provide evidence stewardship, and help clients translate evidence into action. I’m excited to join the team and deliver meaningful impact for our clients and the patients they serve.”
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
Genesis Research Group Appoints Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR
Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence…
Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026
Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it…
MFN Pricing Is Moving Fast – Here’s What Matters
With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it’s a lot to digest. In a new…
ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment
In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on…
Tim Wright Updates ISPOR Europe MFN Pricing Presentation in New Interview
At ISPOR Europe in Glasgow, there were literal queues around the block for Tim Wright’s HEOR Theater presentation ‘MFN Pricing: More Fun to Navigate – A European Roadmap to Success,’ with potentially…
Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212
Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10…
ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs
On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation…
Dave W. Miller interviewed by Paige McGarry on the unique challenges faced by biotech companies
HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.
Genesis Research Group Appoints Tim Wright as Executive Vice President, Access and Pricing
Genesis Research Group, a leading provider of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the appointment of Tim Wright as Executive Vice…
Navigating US market access analytics: A conversation with Ki Park
In the rapidly evolving landscape of healthcare and pharmaceutical market access, data analytics has become a critical component for making informed decisions. We sat down with Ki Park, our Vice…